The Active Pharmaceutical Ingredient (API) size distribution within the final formulation of a drug product is critical as it relates to bioavailability, rates of absorption, and stability of that…
Foreign particulate matter in drug products is a common issue in the pharmaceutical industry that has major impacts on pharmaceutical companies, from both financial and safety aspects. Foreign particulate…
Reference databases catalog data and information for known materials, process and product related materials, and archived foreign particulate.
Proper characterization of pharmaceutical products with respect to particle size and distribution requires that the extent and size of drug particle agglomerates is determined, as well as the size…
May 19, 2015 Establishing bioavailability and proving bioequivalence of inhaled combination therapies can be difficult without addressing two major concerns: accurate and precise particle size distribution data of the individual active pharmaceutical ingredient and source determination of the any existing foreign particulate matter. Raman spectroscopy and Raman chemical imaging have…
Authors & Contributors Cara Plese May 10, 2012 The Mid-Atlantic Association of Forensic Scientists (MAAFS) annual meeting is being held later this month from May 14th through the 18th. MAAFS is one of several regional/state forensic science associations in the United States. Regional meetings are great for scientists to attend because they usually require less travel than…
Download our presentation from 2017 RDD Europe on Advancing the Determination of In Vitro Similarity in Tiotropium Formulations for Inhalation.